Featured Research

from universities, journals, and other organizations

Immunotherapy data heralds new era of lung cancer treatment

Date:
March 26, 2014
Source:
European Society for Medical Oncology (ESMO)
Summary:
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said. For decades, scientists and doctors thought immunotherapy –- treatments that harness the immune system to fight a disease -- was of marginal benefit in lung cancer. However a new class of drugs known as “immunocheckpoint regulators” have shown huge potential, researchers say.

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

Related Articles


For decades, scientists and doctors thought immunotherapy -treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France.

However a new class of drugs known as "immunocheckpoint regulators" have shown huge potential, Soria says. New data on several of these drugs are presented at the conference.

Two of the most interesting immunocheckpoint molecules in this setting are known as PD-1 (programmed death) and PD-L1 (programmed death ligand-1). When these molecules interact in tumours, they prevent immune cells from attacking the cancer cells, allowing them to escape and multiply.

"Blocking PD1 and PDL1 can result in striking and durable responses, with global overall response rates of 20% to 25% as monotherapy in metastatic non-small-cell lung cancer," Soria says. "These impressive results have yet to be confirmed in other trials; nonetheless immune checkpoint inhibitors will most likely become part of daily practice for non-small-cell lung cancer in the near future."

"Immunotherapy has come of age and is here to stay."

At ELCC, Armida D'Incecco from Istituto Toscano Tumori in Livorno, Italy, and colleagues, suggest that combining immunotherapy drugs with other targeted therapies in lung cancer is likely to be beneficial.

D'Incecco's group studied the expression of PD-L1 and PD-1 in a group of 123 non-small-cell lung cancer patients. They also analysed the patients' cancers for mutations in two other molecules, one called EGFR which is the target of existing drugs gefitinib and erlotinib, and another called KRAS.

Those tumours that expressed PD-L1 tended to also carry EGFR mutations, they found. And PD-1 expression in the tissue sample was associated with KRAS mutated status.

Among patients whose tumours carried EGFR mutations, and who were treated with targeted therapies, those whose tumours were also PD-L1 positive took longer to progress, and tended toward longer overall survival than PD-L1 negative patients.

These results suggest a strong correlation between PD-L1 expression and EGFR mutation and between PD-1 expression and KRAS mutations, supporting further investigation of anti-PD-L1 or anti-PD-1 agents in combination with targeted therapies.

Commenting, Jean-Charles Soria notes: "This study suggests that PDL1 expression is correlated with EGFR mutation. If this is true, then immunocheckpoint blockade combination with EGFR tyrosine kinase inhibitors is a major path towards improving outcome of patients who have EGFR-mutant non-small-cell lung cancer." Trials to explore this relationship are underway, he says.


Story Source:

The above story is based on materials provided by European Society for Medical Oncology (ESMO). Note: Materials may be edited for content and length.


Journal Reference:

  1. A. D’Incecco, M. Andreozzi, V. Ludovini, E. Rossi, L. Landi, G. Minuti, G. Fontanini, L. Crinς, L. Terracciano, F. PD-L1 AND PD-1 EXPRESSION IN MOLECULARLY SELECTED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS. Journal of Thoracic Oncology, 2014; 9: S53 DOI: 10.1097/01.JTO.0000445596.04228.a5

Cite This Page:

European Society for Medical Oncology (ESMO). "Immunotherapy data heralds new era of lung cancer treatment." ScienceDaily. ScienceDaily, 26 March 2014. <www.sciencedaily.com/releases/2014/03/140326092242.htm>.
European Society for Medical Oncology (ESMO). (2014, March 26). Immunotherapy data heralds new era of lung cancer treatment. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2014/03/140326092242.htm
European Society for Medical Oncology (ESMO). "Immunotherapy data heralds new era of lung cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2014/03/140326092242.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) — The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) — Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) — Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) — Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins